Lumida
/IOVA
⌘K
Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

IOVA
$8.60USD+5.65%+0.46 today

MARKET CAP

3.9B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$2
$9

AI Summary

Stalk
Buy NowMedium

IOVA exhibits a parabolic continuation phase within a Stage 2 uptrend, with price now pulling back and tightly tracking above rising 9- and 21-day EMAs. Both medium- and short-term biases remain bullish, and current pullbacks offer a favorable entry around these EMAs. Execution should focus on buying pullbacks into the EMA zone with acceptance as confirmation, while a decisive break below the EMAs would invalidate the bullish stance.

  • Q2 revenue $99.3M (+66% YoY) fueled by Amtagvi uptake.
  • Gross margin hit all-time high 56%, up from 41% in Q1.
  • Weak profit margins persist despite R&D expense reductions.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$1.2M$164.1M$263.5M
YoY %+13699.0%+60.6%
P / Sales1601.8x13.1x3.7x
EV / Sales1669.8x13.6x3.9x
Gross Profit, Adj.$156,000$70.8M$90.3M
YoY %+45298.7%+27.5%
Margin %13.1%43.2%34.3%
EV / Gross Profit12727.0x31.5x11.4x
EBITDA, Adj.$-439.1M$-357.6M$-362.3M
YoY %-12.7%+18.6%-1.3%
Margin %-36933.7%-218.0%-137.5%
EV / EBITDA-4.5x-6.2x-2.8x
EBIT$-460.6M$-395.3M$-403.4M
YoY %-15.5%+14.2%-2.0%
Margin %-38735.0%-240.9%-153.1%
EV / EBIT-4.3x-5.6x-2.5x
Net Income$-444.0M$-372.2M$-391.0M
YoY %-12.2%+16.2%-5.1%
Net Margin-37345.4%-226.8%-148.4%
EPS (GAAP)-$1.89-$1.28-$1.09
YoY %+24.1%+32.3%+14.8%